A digest from evidence-based Clinical Practice Guideline for Polycystic Kidney Disease 2020Saori Nishio, Ichiei Narita, Akinari Sekine et al.|Clinical and Experimental Nephrology|2021Cited by 28
Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD)Akinari Sekine, Satoru Muto, Sumi Hidaka et al.|Journal of Clinical Medicine|2022Cited by 26
Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)Kiyotaka Uchiyama, Satoru Muto, Toshio Mochizuki et al.|Clinical and Experimental Nephrology|2021Cited by 16
Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney diseaseHiroshi Kataoka, Satoru Muto, Yosuke Shimada et al.|Clinical and Experimental Nephrology|2023Cited by 5
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5Akinari Sekine, Satoru Muto, Junichi Hoshino et al.|Kidney International Reports|2025Cited by 4